Innoject, Inc. Receives Clearance From the Food & Drug Administration to Market the Hand-Filled Version of Its Auto-Injector Technology

November 12, 2004

ATHENS, TX -- Nov 12, 2004 -- Innoject, Inc. announced today that it has received clearance by the FDA to sell its patented auto-injector product in the United States. This one-time-use disposable device is intended for automatic injection of personalized doses of drugs and biologics. Activated by depressing a button as one would when using a ball point pen, Innoject's flagship product makes it easier for people to receive injections. At no time during the process is the needle visible to the patient, and the automatic needle retraction mechanism is intended to aid in the prevention of accidental needle sticks. This product can only be used as prescribed by and under the supervision of a physician.

Richard D. Gillespie III, President and Co-founder of Innoject, Inc., commented on the news by saying, "We are very pleased with this FDA action and look forward to introducing this advanced auto-injector technology to the marketplace. We are confident this product will make a real difference in the lives of people that must receive injectable medicines."

Innoject, Inc. CEO Richard M. Winters said, "Our vision of improving the quality of life of patients who are physically unable or unwilling to use currently available self-injection technology is becoming a reality with this exciting first product. The Confi·Dose™ product offers superior features over the other available options in many settings. Companion products that we are developing with the assistance of a grant from National Institutes of Health (NIH) will soon provide alternatives to even more patients."

About Innoject, Inc.

Innoject, Inc. is a privately held company dedicated to improving the science of injectable drug delivery. The company's flagship product, the Confi·Dose™ auto-injector, has recently been cleared by the FDA. Additional products are currently in late stage development. The Confi·Dose™ Auto-injector is designed to automate all three steps of the injection process -- needle insertion, drug delivery, and needle withdrawal -- all with the push of a button. Innoject, Inc. has its principal facility in Athens, Texas, and offices in Clarksville, Texas.

You can learn more about Innoject's auto-injector technology by visiting the company's website at www.innoject.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those related to: the acceptance of Innoject Inc.'s product offerings by other companies; and the successful development, FDA clearance, and commercialization of products and technologies in the pipeline. Innoject Inc. cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially. Such risks and uncertainties include all of the risks and factors identified from time to time in the Innoject Inc.'s reports filed with the U.S. Securities and Exchange Commission. Innoject Inc. claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Contact:
Richard M. Winters, CEO
Innoject, Inc.
P.O. Box 469
Athens, TX 75751
Phone: (972) 722-0827
dick.winters@innoject.com
http://www.innoject.com